Showing 1361-1370 of 1535 results for "".
- FDA Approves Humira Biosimilarhttps://practicaldermatology.com/news/fda-approves-humira-biosimilar/2458424/The U.S. Food and Drug Administration today approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases. Amjevita is approved for the following indications in adult patients: ·  
- African-American Organ Transplant Recipients at Risk for Skin Cancerhttps://practicaldermatology.com/news/african-american-organ-transplant-recipients-at-risk-for-skin-cancer/2458428/All organ transplant recipients, regardless of race, should receive routine, total-body screenings for skin cancer, according to researchers from Drexel University College of Medicine in Philadelphia. Out of 259 nonwhite transplant recipients who were evaluated in the study, 19 skin
- IV Glutathione for Skin Whitening is Risky Business, UK Doctor Warnshttps://practicaldermatology.com/news/iv-glutathione-for-skin-whitening-is-risky-business-uk-doctor-warns/2458444/Skin bleaching with IV glutathione is on the rise, despite potential risks, warns a doctor in The BMJ. Both the US Food and Drug Administration (FDA) and the Dermatology Society in the Philippines -- where the practice i
- FDA Bans 19 Ingredients from Hand Soapshttps://practicaldermatology.com/news/fda-no-more-antibacterials-allowed-in-consumer-soaps/2458446/Antibacterial soaps will soon be gone from store shelves, according to a new rule from the US Food and Drug Administration (FDA). This
- FDA Approves Enbrel Biosimilarhttps://practicaldermatology.com/news/fda-approves-enbrel-biosimilar/2458451/The U.S. Food and Drug Administration (FDA) approved Erelzi for multiple inflammatory diseases. Erelzi is a biosimilar to Enbrel (etanercept), which was originally licensed in 1998. The move is no surprise given the unanimous backing of an FDA advisory arm last month. There are now
- FDA Greenlights NDA for New Impetigo Treatmenthttps://practicaldermatology.com/news/fda-greenlights-nda-for-new-impetigo-treatment/2458449/The U.S. Food and Drug Administration (FDA) has accepted Medimetriks Pharmaceuticals, Inc.'s New Drug Application (NDA) for their novel impetigo treatment, ozenoxacin cream, 1%. Ozenoxacin cream is a non-fluorinated quinolone. The
- Chris Payne Named Chief Marketing Officer at PCA Skinhttps://practicaldermatology.com/news/chris-payne-named-chief-marketing-officer-at-pca-skin/2458454/Chris Payne has been named Chief Marketing Officer at Scottsdale, AZ-based PCA Skin. In this role, Payne will be responsible for leading all marketing and communication initiatives to drive growth of PCA SKIN through both professional and consum
- Freedom Laser Therapy Launches iRESTORE Hair Growth Systemhttps://practicaldermatology.com/news/freedom-laser-therapy-launches-irestore-hair-growth-system/2458457/Freedom Laser Therapy is rolling out the iRestore Hair Growth System. The hands-free iRestore Hair Growth System is US Food and Drug Administr
- FDA Cracks Down on Mercury in Anti-Aging Productshttps://practicaldermatology.com/news/fda-cracks-down-on-mercury-in-anti-aging-products/2458488/The U.S. Food and Drug Administration is re-issuing a warning about the dangers of mercury in skin creams, beauty and antiseptic soaps, and lotions. In the past few years, the FDA and state health officials
- Syneron Candela's PicoWay Picosecond Laser Receives U.S. FDA Clearance for Ultra-Short 785nm Wavelengthhttps://practicaldermatology.com/news/syneron-candelas-picoway-picosecond-laser-receives-us-fda-clearance-for-ultra-short-785nm-wavelength/2458489/And then there were three. The U.S. Food and Drug Administration (FDA) has cleared Syneron Medical Ltd.’s PicoWay® picosecond laser for a new ultra-short 785nm wavelength. The addition of the new